Pacer Advisors Inc. Sells 566,516 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Pacer Advisors Inc. cut its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 99.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,827 shares of the specialty pharmaceutical company's stock after selling 566,516 shares during the quarter. Pacer Advisors Inc.'s holdings in ANI Pharmaceuticals were worth $101,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after purchasing an additional 340,854 shares during the period. Bank of Montreal Can acquired a new stake in ANI Pharmaceuticals in the third quarter worth $13,043,000. Mizuho Markets Americas LLC acquired a new stake in ANI Pharmaceuticals in the third quarter worth $11,670,000. Barclays PLC raised its holdings in ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock worth $8,534,000 after purchasing an additional 135,003 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in ANI Pharmaceuticals by 67.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company's stock worth $17,226,000 after purchasing an additional 125,438 shares during the period. 76.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, December 11th. HC Wainwright restated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective on the stock. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a report on Tuesday, October 22nd. Finally, Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $77.71.

Insiders Place Their Bets

In other news, CEO Nikhil Lalwani sold 33,481 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares of the company's stock, valued at $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,381 shares of company stock worth $2,441,556 in the last quarter. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock traded up $0.36 during midday trading on Friday, hitting $60.55. 255,344 shares of the company were exchanged, compared to its average volume of 182,820. The firm has a market capitalization of $1.27 billion, a P/E ratio of -110.09 and a beta of 0.74. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm's 50 day moving average price is $56.71 and its two-hundred day moving average price is $58.49. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. The business had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals's revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.05 EPS. As a group, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.